Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation.
Bleeding remains a potential complication for patients requiring extracorporeal life support systems. Recombinant activated factor VII (rFVIIa) is one of the drugs used in controlling bleeding. Its use is generally found to be safe. We report a paediatric patient who developed fatal thrombosis with the use of rFVIIa whilst on extracorporeal membrane oxygenation and discuss the possible factors that lead to fatal thrombosis.
Chalwin
Richard P
RP
Department of ECMO, Glenfield Hospital, Leicester, LE3 9QP, UK.
Tiruvoipati
Ravindranath
R
Peek
Giles J
GJ
D003029:Coagulants / Q000009:adverse effects*; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects*; D015942:Factor VIIa / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007223:Infant; D011994:Recombinant Proteins / Q000009:adverse effects; D013927:Thrombosis / Q000209:etiology*
D003029:Coagulants; D011994:Recombinant Proteins; D015942:Factor VIIa